Positron emission tomography-computed tomography (PET-CT) is a widely accepted imaging technique for initial staging and for detecting sites of disease recurrence in patients with prostate cancer; this has particularly been the case since the introduction of prostate-specific membrane antigen (PSMA) radiotracers [3]. This evidence concerns the gene FOLH1 and prostate carcinoma.